Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan
The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
Irinotecan (CPT-11) is a key drug for the treatment of various cancers. CPT-11 can be considered to be a prodrug, since it needs to be activated into the toxic drug SN-38 by the enzyme carboxylesterase. However, CPT-11 may induce severe diarrhea and bone marrow suppression as adverse effects, thus leading to treatment interruption. The tumor-specific activation of CPT-11 is a possible strategy to avoid the severe toxicities by reducing the serum concentration of CPT-11. In this study, we constructed human liver carboxylesterase-2 fused with anticarcinoembryonic antigen (CEA) scFv as a targeting molecule. The recombinant enzyme anchors onto the tumor cell surface CEA, and thus metabolize CPT-11 extracellularly. In addition a secreted tumor-targeted form of carboxylesterase should help prevent the leakage of the enzyme from the site of the tumor into the circulation. This fusion protein showed CPT-11 activation to SN-38 and specific binding to CEA-expressing cells. In combination with CPT-11, the recombinant carboxylesterase protein exerted antiproliferative effects on human cancer cells. This recombinant enzyme is, therefore, a promising new tool in enzyme prodrug therapy for the treatment of carcinoma with CPT-11.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple preclinical studies have shown that selectively increasing the activity of CES in CRC by viruses can improve the efficacy of irinotecan [91,92,93].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [91]
Citations
Cites
The use of avidin-biotin interaction in immunoenzymatic techniques.
Guesdon, J. L., Ternynck, T., & Avrameas, S. (1979) · Journal of Histochemistry & Cytochemistry · doi:10.1177/27.8.90074 · Cited by 1,718
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Hammarström, S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0119 · Cited by 1,300
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., DeLand, F., Kim, E., Bennett, S., Primus, F. J., van Nagell, J. R., Estes, N., DeSimone, P., & Rayburn, P. (1978) · New England Journal of Medicine · doi:10.1056/nejm197806222982503 · Cited by 756
Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7478-7491.2005 · Cited by 427
Tanizawa, A., Fujimori, A., Fujimori, Y., & Pommier, Y. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.836 · Cited by 300
Antibody directed enzymes revive anti-cancer prodrugs concept
Bagshawe, K. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.237 · Cited by 280
Strategies for enzyme/prodrug cancer therapy.
Xu, G., & McLeod, H. L. (2001) · PubMed · Cited by 279
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
SATOH, T., HOSOKAWA, M., ATSUMI, R., SUZUKI, W., HAKUSUI, H., & NAGAI, E. (1994) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.17.662 · Cited by 174
Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., & Fukuoka, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1068 · Cited by 169
Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna, R., Morton, C. L., Danks, M. K., & Potter, P. M. (2000) · PubMed · Cited by 158
Sanghani, S. P., Quinney, S. K., Fredenburg, T. B., Davis, W. I., Murry, D. J., & BOSRON, W. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.505 · Cited by 145
Takayama, K., Ueno, H., Nakanishi, Y., Sakamoto, T., Inoue, K., Shimizu, K., Oohashi, H., & Hara, N. (2000) · PubMed · Cited by 142
Self-citationGastrointestinal toxicity or irinotecan.
Hecht, J. R. (1998) · PubMed · Cited by 126
Syrigos, K. N., & Epenetos, A. A. (1999) · PubMed · Cited by 87
Targeting enzymes for cancer therapy: old enzymes in new roles
Deonarain, M. P., & Epenetos, A. A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.400 · Cited by 74
Kurita, A., & Kaneda, N. (1999) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(98)00554-4 · Cited by 71
Wierdl, M., Morton, C. L., Weeks, J. K., Danks, M. K., Harris, L. C., & Potter, P. M. (2001) · PubMed · Cited by 63
Abe, H., Kuroki, M., Tachibana, K., Li, T., Awasthi, A., Ueno, A., Matsumoto, H., Imakiire, T., Yamauchi, Y., Yamada, H., et al. (2002) · PubMed · Cited by 48
Self-citationRaben, D., Buchsbaum, D. J., Mb, K., Me, R., Gillespie, G. Y., Grizzle, W. E., Liu, T., & Curiel, D. (1996) · PubMed · Cited by 44
Self-citationSecreted and tumour targeted human carboxylesterase for activation of irinotecan
Oosterhoff, D., Pinedo, H. M., van der Meulen, I. H., de Graaf, M., Sone, T., Kruyt, F. A. E., van Beusechem, V. W., Haisma, H. J., & Gerritsen, W. R. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600519 · Cited by 41
Self-citationMinagawa, Y., Kigawa, J., Ishihara, H., Itamochi, H., & Terakawa, N. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02976.x · Cited by 38
Irvin, W. P., Price, F. V., Bailey, H. H., Gelder, M. S., Rosenbluth, R. J., Durivage, H. J., & Potkul, R. K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980115)82:2<334::aid-cncr13>3.0.co;2-# · Cited by 36
Kuroki, M., Arakawa, F., Haruno, M., MURAKAMI, M., Wakisaka, M., Higuchi, H., Oikawa, S., Nakazato, H., & Matsuoka, Y. (1992) · Hybridoma · doi:10.1089/hyb.1992.11.391 · Cited by 34
Self-citationOosterhoff, D., Overmeer, R. M., de Graaf, M., van der Meulen, I. H., Giaccone, G., van Beusechem, V. W., Haisma, H. J., Pinedo, H. M., & Gerritsen, W. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602362 · Cited by 26
Cited by
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Swami, U., Goel, S., & Mani, S. (2013) · Current Drug Targets · doi:10.2174/1389450111314070007 · Cited by 88
Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 74
Zhao, D., Zhang, H., Tao, W., Wei, W., Sun, J., & He, Z. (2017) · Biomaterials Science · doi:10.1039/c6bm00884d · Cited by 55
Metadata
- Authors
- Uchino, J., Takayama, K., Harada, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, M., & Nakanishi, Y.
- Affiliations
- Kyushu University (JP)
- Setsunan University (JP)
- University of Alabama at Birmingham (US)
- Fukuoka University (JP)
- Corresponding author
- Takayama, K
- Venue
- Cancer Gene Therapy
- Published
- 2007-12-21
- Volume
- 15
- Issue
- 2
- Pages
- 94-100
- ISSN
- 0929-1903 (ISSN-L)
- 1476-5500
- OpenAlex
- W1969759353
- Cited by
- 21
- References
- 28
- Citations by year
- 2023: 4 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 2 · 2013: 2 · 2012: 2
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cancer Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme Catalysis and Immobilization
- Keywords
- irinotecan, CE2, carcinoembryonic antigen, scFv, enzyme prodrug therapy, fusion protein, antiproliferative activity, drug toxicity reduction
- MeSH terms
- Irinotecan, Antineoplastic Agents, Phytogenic, Camptothecin, Carcinoembryonic Antigen, Dose-Response Relationship, Immunologic, HeLa Cells, Humans, Immunoglobulin Variable Region, Recombinant Fusion Proteins, Gene Targeting, Carboxylesterase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.